Pyxis Oncology to Present MICVO Phase 1 Monotherapy Data at EORTC-NCI-AACR Symposium
Pyxis Oncology announced a late-breaking oral presentation of micvotabart pelidotin monotherapy data, alongside two poster presentations, at the EORTC-NCI-AACR symposium.